OSI Pharmaceuticals reports total revenues of $111 million for the third quarter of 2009

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today its financial results for the Company’s third quarter ended September 30, 2009. The Company reported total revenues from continuing operations of $111 million for the third quarter of 2009 compared to revenues of $95 million for the third quarter of 2008, an 18% increase over the prior year period. Total worldwide net sales of Tarceva for the three and nine months ended September 30, 2009, as reported to the Company by its collaborator Roche, were approximately $301 million and $870 million, respectively.

The Company reported net income from continuing operations of $17.9 million (or $0.30 per share) for the three months ended September 30, 2009, compared to $31.4 million (or $0.53 per share) for the three months ended September 30, 2008. 2009 is the first year of financial reporting in which OSI has shown a full tax provision on its earnings. Adjusting for non-cash tax expense (to reflect OSI’s actual cash tax rate of approximately 3%), restructuring and other charges related to our consolidation of U.S. operations, expense related to equity-based compensation, non-cash interest expense on our convertible notes, and certain other items detailed in the attached reconciliation of GAAP to non-GAAP financial measures, the Company reported that non-GAAP net income from continuing operations increased 27% to $51 million from $40 million and non-GAAP earnings per share increased 26.5% to $0.81 from $0.64, for the three months ended September 30, 2009 and 2008, respectively.

Total revenues from continuing operations for the third quarter of 2009 are comprised of the following key items:

• Tarceva Related Revenues of $89 million for the third quarter of 2009 compared to $81 million for the third quarter of 2008, based primarily on the following:
  • Net revenues from the unconsolidated joint business for Tarceva of $51 million for the third quarter of 2009, compared to $46 million in the third quarter of 2008, arising from the Company's co-promotion arrangement with Genentech, a wholly-owned member of the Roche Group. The net revenues are based on total U.S. Tarceva sales of $118 million for the third quarter of 2009, compared to $110 million in the third quarter of 2008, as reported to OSI by Roche. Sales for the three months ended September 30, 2008 were negatively impacted by approximately $11 million of net reserve adjustments primarily due to higher than anticipated product returns related to expiring inventory, and sales for the three months ended September 30, 2009 were negatively impacted by a net reserve adjustment of approximately $2 million.
  • Royalties on product licenses of $37 million for the third quarter of 2009 compared to $34 million in the third quarter of 2008 from Roche for sales of Tarceva outside of the United States. Royalty revenues are based on total rest of world sales of $183 million for the third quarter of 2009. As disclosed by Roche, year to date growth in local currencies (excluding Japan) was approximately 16%, and was 30% in Japan, compared to the prior year.
• Other Revenues of $23 million for the third quarter of 2009 compared to $14 million in the third quarter of 2008, primarily based upon royalties related to worldwide non-exclusive licensing agreements under the Company's DP-IV patent portfolio covering the use of DP-IV inhibitors for treatment of type 2 diabetes. The three months ended September 30, 2009 included a $5 million milestone payment related to a non-exclusive licensing agreement under the Company’s DP-IV patent portfolio.

Operating Expenses

Operating expenses from continuing operations for the third quarter of 2009 were $71 million compared to $58 million for the same period last year. Research and development expenses for the third quarter of 2009 were $39 million compared to $33 million for the same period last year. The increase was primarily driven by higher clinical trial expense. The Company also recognized a $5 million in-process research and development charge related to its recently announced expansion of its drug discovery and translational research collaboration with AVEO Pharmaceuticals Inc. Selling, general and administrative expenses for the third quarter of 2009 were $25 million compared to $22 million for the same period last year. The Company also recognized restructuring costs of $1.1 million related to its previously announced plans to consolidate its U.S. operations onto a single campus at its recently acquired site in Ardsley, New York.

Taxes and Interest Expense

Beginning in 2009, the Company is required to report its tax provision at its full effective tax rate, which is estimated at approximately 39%. However, the Company expects to continue paying taxes at the lower alternative minimum tax rates as it continues to utilize its net operating loss carryforwards (NOLs). In addition to the 39% tax rate, the income tax provision for the three and nine months ended September 30, 2009 includes a $3.3 million charge related to a valuation reserve adjustment as a result of consolidating operations into a single site. The results also reflect the retrospective application of Accounting Standards Codification Subtopic 470-20 which includes guidance for convertible debt instruments that may be settled in cash upon conversion, resulting in higher interest expense reported in both 2009 and 2008.

Net Income Including Discontinued Operations

The Company's net income including results from discontinued operations was $17.6 million (or $0.30 per share) for the third quarter of 2009 compared with a net income of $51.6 million (or $0.87 per share) for the same period last year.